RT Magazine

06/24/2026

This year's measles toll climbs to over 2,000 cases and is already nearing 2025's total
https://buff.ly/F5JsiuI

A total of 2,073 measles cases have been reported in the United States in 2026 -- nearly as many as the entire 2025 calendar year.

06/24/2026

8 recommendations for asthma education
https://buff.ly/ANASk7p

Eight recommendations for effective patient education regarding inhaled medications used in treating asthma symptoms and flare-ups.

06/04/2026

Our featured report on overnight pulse oximetry is now available. https://buff.ly/rfKZePg

Explore its applications for monitoring cardiorespiratory patients, prescreening OSA, and assessing dental sleep appliances

05/28/2026

A 28-year-old cystic fibrosis patient underwent a 36-hour quadruple organ transplant for both lungs, a liver, and a kidney
https://buff.ly/Q8iLX2o

A 28-year-old cystic fibrosis patient underwent a 36-hour quadruple organ transplant for both lungs, a liver, and a kidney.

05/27/2026

Ventilator recall alert from the FDA
https://buff.ly/DIuCOIX

React Health is removing certain VOCSN V+Pro units due to a potential oxygen leak condition prior to or during ventilation.

05/27/2026

35% of women report menopause-related sleep disruptions
https://buff.ly/FynGBcs

More than 35% of women age 45-64 report frequent nighttime waking and night sweats caused by menopause hormonal changes.

05/27/2026

2-time NASCAR champ Kyle Busch died last week from severe pneumonia that escalated into sepsis
https://buff.ly/ea9imAC

Two-time NASCAR champion driver Kyle Busch (41) died Thursday from severe pneumonia that progressed into sepsis.

05/20/2026

Early use of fast identification and antimicrobial susceptibility testing could prevent 36,200 deaths and 84,400 sepsis cases annually
https://buff.ly/dj1uEvr

A new analysis shows that early use of rapid testing for bloodstream infections reduces sepsis progression and healthcare expenses.

05/19/2026

Tozorakimab reduced annual exacerbations for moderate-to-severe COPD patients, including former and current smokers
https://buff.ly/Xh7snXf

Tozorakimab significantly lowered the rate of moderate-to-severe respiratory worsening in COPD patients regardless of smoking history.

05/19/2026

Phase 1 trial results for the inhaled nitric oxide therapy ALX1 expected at ATS 2026
https://buff.ly/jCU6vH1

Phase 1 results for the inhaled drug candidate ALX1 focus on safety and pharmacokinetics for the treatment of serious lung diseases.